MannKind Operating Expenses 2010-2025 | MNKD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

MannKind operating expenses from 2010 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

MannKind operating expenses from 2010 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$217.3B
Amgen (AMGN)	$160.8B
Gilead Sciences (GILD)	$136.6B
Vertex Pharmaceuticals (VRTX)	$120.6B
Bristol Myers Squibb (BMY)	$96B
CSL (CSLLY)	$78.5B
GSK (GSK)	$78.4B
Regeneron Pharmaceuticals (REGN)	$59.2B
Alnylam Pharmaceuticals (ALNY)	$42.1B
Argenex SE (ARGX)	$35.4B
BioNTech SE (BNTX)	$27B
Royalty Pharma (RPRX)	$20B
Insmed (INSM)	$19.8B
Biogen (BIIB)	$18.8B
Illumina (ILMN)	$15.3B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$14B
Incyte (INCY)	$13.4B
Moderna (MRNA)	$12.4B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.2B
QIAGEN (QGEN)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exact Sciences (EXAS)	$10.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.1B
Roivant Sciences (ROIV)	$7.8B
Regencell Bioscience Holdings (RGC)	$7.6B